Tuberculosis DNA vaccine - Sequella

Drug Profile

Tuberculosis DNA vaccine - Sequella

Alternative Names: Heat shock protein 65 DNA vaccine; hsp65 DNA vaccine

Latest Information Update: 12 Oct 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institute for Medical Research
  • Developer National Institute for Medical Research; Sequella
  • Class DNA vaccines; Gene therapies; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Tuberculosis

Most Recent Events

  • 22 Feb 2010 Discontinued - Preclinical for Tuberculosis in United Kingdom (unspecified route)
  • 22 Feb 2010 Discontinued - Preclinical for Tuberculosis in USA (unspecified route)
  • 21 Aug 2007 Preclinical development is ongoing in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top